Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilateral Greater Occipital Nerve Blocks vs Ten Peripheral Nerve Blocks for Episodic Migraine
NCT05734625Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jul 2023
- Primary completion
- Feb 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bupivacaine hydrochloride 0.75% injection and methylprednisolone injection in episodic migraine (2 arms), sponsored by Mayo Clinic. Primary endpoint: Elimination of acute headache at 20 minutes. Started Jul 2023; status: recruiting.
02
Drugs
bupivacaine hydrochloride 0.75% injectionmethylprednisolone injection
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT05734625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734625.